factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fact | preserve | 231-233 | 231-233 | T24 | in | TREATS | 231 | 233 | preserve | 218-230 | 218-230 | T19 | theophylline | BiologicallyActiveSubstance | 218 | 230 | preserve | 264-270 | 264-270 | T22 | asthma | DiseaseOrSyndrome | 264 | 270 | A3 | STUDY OBJECTIVES: To compare the efficacy, safety, and effects on sleep quality of salmeterol and extended-release theophylline in patients with nocturnal asthma. | 97-271 | 97 | 271 | STUDY OBJECTIVES: To compare the efficacy, safety, and effects on sleep quality of salmeterol and extended-release @SUBJECT$ @PREDICAT$ patients with nocturnal @OBJECT$ . |
Fact | preserve | 231-233 | 231-233 | T24 | in | TREATS | 231 | 233 | preserve | 186-196 | 186-196 | T17 | salmeterol | OrganicChemical | 186 | 196 | preserve | 264-270 | 264-270 | T22 | asthma | DiseaseOrSyndrome | 264 | 270 | A4 | STUDY OBJECTIVES: To compare the efficacy, safety, and effects on sleep quality of salmeterol and extended-release theophylline in patients with nocturnal asthma. | 97-271 | 97 | 271 | STUDY OBJECTIVES: To compare the efficacy, safety, and effects on sleep quality of @SUBJECT$ and extended-release theophylline @PREDICAT$ patients with nocturnal @OBJECT$ . |
Fact | preserve | 1672-1680 | 1672-1680 | T132 | compared | compared_with | 1,672 | 1,680 | preserve | 1539-1549 | 1539-1549 | T120 | salmeterol | OrganicChemical | 1,539 | 1,549 | preserve | 1686-1698 | 1686-1698 | T130 | theophylline | BiologicallyActiveSubstance | 1,686 | 1,698 | A5 | The use of salmeterol significantly increased the percentage of days and nights with no albuterol use and decreased daytime albuterol use compared with theophylline and placebo (p < or = 0.05). | 1522-1734 | 1,522 | 1,734 | The use of @SUBJECT$ significantly increased the percentage of days and nights with no albuterol use and decreased daytime albuterol use @PREDICAT$ with @OBJECT$ and placebo (p < or = 0.05). |
Fact | preserve | 118-125 | 118-125 | T23 | compare | compared_with | 118 | 125 | preserve | 186-196 | 186-196 | T17 | salmeterol | OrganicChemical | 186 | 196 | preserve | 218-230 | 218-230 | T19 | theophylline | BiologicallyActiveSubstance | 218 | 230 | A6 | STUDY OBJECTIVES: To compare the efficacy, safety, and effects on sleep quality of salmeterol and extended-release theophylline in patients with nocturnal asthma. | 97-271 | 97 | 271 | STUDY OBJECTIVES: To @PREDICAT$ the efficacy, safety, and effects on sleep quality of @SUBJECT$ and extended-release @OBJECT$ in patients with nocturnal asthma. |
Fact | preserve | 604-608 | 604-608 | T61 | with | PROCESS_OF | 604 | 608 | preserve | 619-625 | 619-625 | T53 | asthma | DiseaseOrSyndrome | 619 | 625 | preserve | 557-565 | 557-565 | T49 | patients | PatientOrDisabledGroup | 557 | 565 | A7 | PATIENTS: Male and female patients who were at least 18 years old with nocturnal asthma (baseline FEV1, 50 to 90% of predicted) and who required regular bronchodilator therapy. | 531-720 | 531 | 720 | PATIENTS: Male and female @OBJECT$ who were at least 18 years old @PREDICAT$ nocturnal @SUBJECT$ (baseline FEV1, 50 to 90% of predicted) and who required regular bronchodilator therapy. |
Fact | preserve | 243-247 | 243-247 | T26 | with | PROCESS_OF | 243 | 247 | preserve | 264-270 | 264-270 | T22 | asthma | DiseaseOrSyndrome | 264 | 270 | preserve | 234-242 | 234-242 | T20 | patients | PatientOrDisabledGroup | 234 | 242 | A9 | STUDY OBJECTIVES: To compare the efficacy, safety, and effects on sleep quality of salmeterol and extended-release theophylline in patients with nocturnal asthma. | 97-271 | 97 | 271 | STUDY OBJECTIVES: To compare the efficacy, safety, and effects on sleep quality of salmeterol and extended-release theophylline in @OBJECT$ @PREDICAT$ nocturnal @SUBJECT$ . |
Fact | preserve | 231-233 | 231-233 | T24 | in | TREATS | 231 | 233 | preserve | 186-196 | 186-196 | T17 | salmeterol | OrganicChemical | 186 | 196 | preserve | 234-242 | 234-242 | T20 | patients | PatientOrDisabledGroup | 234 | 242 | A10 | STUDY OBJECTIVES: To compare the efficacy, safety, and effects on sleep quality of salmeterol and extended-release theophylline in patients with nocturnal asthma. | 97-271 | 97 | 271 | STUDY OBJECTIVES: To compare the efficacy, safety, and effects on sleep quality of @SUBJECT$ and extended-release theophylline @PREDICAT$ @OBJECT$ with nocturnal asthma. |
Fact | preserve | 56-58 | 56-58 | T9 | in | PROCESS_OF | 56 | 58 | preserve | 28-33 | 28-33 | T3 | sleep | OrganismFunction | 28 | 33 | preserve | 59-67 | 59-67 | T5 | patients | PatientOrDisabledGroup | 59 | 67 | A11 | Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma. | 0-96 | 0 | 96 | Salmeterol vs theophylline: @SUBJECT$ and efficacy outcomes @PREDICAT$ @OBJECT$ with nocturnal asthma. |
Fact | preserve | 1294-1296 | 1294-1296 | T116 | to | higher_than | 1,294 | 1,296 | preserve | 1263-1273 | 1263-1273 | T97 | Salmeterol | OrganicChemical | 1,263 | 1,273 | preserve | 1297-1309 | 1297-1309 | T99 | theophylline | BiologicallyActiveSubstance | 1,297 | 1,309 | A13 | Salmeterol was superior to theophylline (p < or = 0.05) in maintaining nocturnal FEV1 levels and was superior to placebo (p < or = 0.05) in improving morning and evening peak expiratory flow (PEF) and in decreasing nighttime albuterol use. | 1263-1521 | 1,263 | 1,521 | @SUBJECT$ was superior @PREDICAT$ @OBJECT$ (p < or = 0.05) in maintaining nocturnal FEV1 levels and was superior to placebo (p < or = 0.05) in improving morning and evening peak expiratory flow (PEF) and in decreasing nighttime albuterol use. |
Fact | preserve | 11-13 | 11-13 | T8 | vs | compared_with | 11 | 13 | preserve | 0-10 | 0-10 | T1 | Salmeterol | OrganicChemical | 0 | 10 | preserve | 14-26 | 14-26 | T2 | theophylline | BiologicallyActiveSubstance | 14 | 26 | A14 | Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma. | 0-96 | 0 | 96 | @SUBJECT$ @PREDICAT$ @OBJECT$ : sleep and efficacy outcomes in patients with nocturnal asthma. |
Fact | preserve | 68-72 | 68-72 | T10 | with | PROCESS_OF | 68 | 72 | preserve | 89-95 | 89-95 | T7 | asthma | DiseaseOrSyndrome | 89 | 95 | preserve | 59-67 | 59-67 | T5 | patients | PatientOrDisabledGroup | 59 | 67 | A15 | Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma. | 0-96 | 0 | 96 | Salmeterol vs theophylline: sleep and efficacy outcomes in @OBJECT$ @PREDICAT$ nocturnal @SUBJECT$ . |
Fact | preserve | 550-565 | 557-565 | T60 | female patients | PROCESS_OF | 550 | 565 | preserve | 550-556 | 550-556 | T48 | female | OrganismAttribute | 550 | 556 | preserve | 557-565 | 557-565 | T49 | patients | PatientOrDisabledGroup | 557 | 565 | A16 | PATIENTS: Male and female patients who were at least 18 years old with nocturnal asthma (baseline FEV1, 50 to 90% of predicted) and who required regular bronchodilator therapy. | 531-720 | 531 | 720 | PATIENTS: Male and @SUBJECT$ @PREDICAT$ @OBJECT$ who were at least 18 years old with nocturnal asthma (baseline FEV1, 50 to 90% of predicted) and who required regular bronchodilator therapy. |
Fact | preserve | 231-233 | 231-233 | T24 | in | TREATS | 231 | 233 | preserve | 218-230 | 218-230 | T19 | theophylline | BiologicallyActiveSubstance | 218 | 230 | preserve | 234-242 | 234-242 | T20 | patients | PatientOrDisabledGroup | 234 | 242 | A17 | STUDY OBJECTIVES: To compare the efficacy, safety, and effects on sleep quality of salmeterol and extended-release theophylline in patients with nocturnal asthma. | 97-271 | 97 | 271 | STUDY OBJECTIVES: To compare the efficacy, safety, and effects on sleep quality of salmeterol and extended-release @SUBJECT$ @PREDICAT$ @OBJECT$ with nocturnal asthma. |
Probable | preserve | 1304-1312 | 1304-1312 | T98 | improved | TREATS | 1,304 | 1,312 | preserve | 1295-1303 | 1295-1303 | T88 | exercise | DailyOrRecreationalActivity | 1,295 | 1,303 | preserve | 1322-1334 | 1322-1334 | T90 | hypertension | DiseaseOrSyndrome | 1,322 | 1,334 | A1 | Our results indicated swimming training exercise improved not only hypertension but also muscle insulin sensitivity and GLUT4 protein expression in SHRSP. | 1249-1415 | 1,249 | 1,415 | Our results indicated swimming training @SUBJECT$ @PREDICAT$ not only @OBJECT$ but also muscle insulin sensitivity and GLUT4 protein expression in SHRSP. |
Fact | preserve | 1406-1408 | 1406-1408 | T99 | in | PROCESS_OF | 1,406 | 1,408 | preserve | 1357-1376 | 1365-1376 | T92 | insulin sensitivity | PathologicFunction | 1,357 | 1,376 | preserve | 1409-1414 | 1409-1414 | T97 | SHRSP | Mammal | 1,409 | 1,414 | A2 | Our results indicated swimming training exercise improved not only hypertension but also muscle insulin sensitivity and GLUT4 protein expression in SHRSP. | 1249-1415 | 1,249 | 1,415 | Our results indicated swimming training exercise improved not only hypertension but also muscle @SUBJECT$ and GLUT4 protein expression @PREDICAT$ @OBJECT$ . |
Fact | preserve | 21-28 | 21-28 | T10 | reduces | PREVENTS | 21 | 28 | preserve | 12-20 | 12-20 | T2 | swimming | DailyOrRecreationalActivity | 12 | 20 | preserve | 29-43 | 35-43 | T3 | blood pressure | Finding | 29 | 43 | A3 | Training in swimming reduces blood pressure and increases muscle glucose transport activity as well as GLUT4 contents in stroke-prone spontaneously hypertensive rats. | 0-178 | 0 | 178 | Training in @SUBJECT$ @PREDICAT$ @OBJECT$ and increases muscle glucose transport activity as well as GLUT4 contents in stroke-prone spontaneously hypertensive rats. |
Fact | preserve | 497-499 | 497-499 | T35 | in | PROCESS_OF | 497 | 499 | preserve | 453-473 | 461-473 | T28 | genetic hypertension | DiseaseOrSyndrome | 453 | 473 | preserve | 516-533 | 529-533 | T33 | Wistar Kyoto rats | Mammal | 516 | 533 | A4 | We studied the relationship between genetic hypertension and insulin resistance in SHRSP and Wistar Kyoto rats (WKY) as a control. | 411-553 | 411 | 553 | We studied the relationship between @SUBJECT$ and insulin resistance @PREDICAT$ SHRSP and @OBJECT$ (WKY) as a control. |
Fact | preserve | 926-962 | 955-962 | T64 | plasma membrane GLUT4 protein | PART_OF | 926 | 962 | preserve | 949-962 | 955-962 | T59 | GLUT4 protein | AminoAcidPeptideOrProtein | 949 | 962 | preserve | 926-941 | 933-941 | T58 | plasma membrane | CellComponent | 926 | 941 | A5 | The swimming training also resulted in an approximately 20% increase in the insulin-stimulated glucose transport activity (p < 0.05) of soleus muscle strips and an approximately 3-fold increase in the plasma membrane GLUT4 protein expression (p < 0.01) in SHRSP. | 712-994 | 712 | 994 | The swimming training also resulted in an approximately 20% increase in the insulin-stimulated glucose transport activity (p < 0.05) of soleus muscle strips and an approximately 3-fold increase in the @OBJECT$ @PREDICAT$ @SUBJECT$ expression (p < 0.01) in SHRSP. |
Fact | preserve | 1218-1220 | 1218-1220 | T84 | of | PART_OF | 1,218 | 1,220 | preserve | 1202-1217 | 1211-1217 | T79 | skeletal muscle | Tissue | 1,202 | 1,217 | preserve | 1221-1226 | 1221-1226 | T82 | SHRSP | Mammal | 1,221 | 1,226 | A6 | There was no difference in insulin resistance in skeletal muscle of SHRSP as compared with WKY. | 1147-1248 | 1,147 | 1,248 | There was no difference in insulin resistance in @SUBJECT$ @PREDICAT$ @OBJECT$ as compared with WKY. |
Fact | preserve | 188-196 | 188-196 | T18 | improves | TREATS | 188 | 196 | preserve | 179-187 | 179-187 | T13 | Exercise | DailyOrRecreationalActivity | 179 | 187 | preserve | 204-223 | 212-223 | T15 | insulin sensitivity | PathologicFunction | 204 | 223 | A7 | Exercise improves muscle insulin sensitivity and GLUT4 contents. | 179-243 | 179 | 243 | @SUBJECT$ @PREDICAT$ muscle @OBJECT$ and GLUT4 contents. |
Fact | preserve | 124-126 | 124-126 | T12 | in | PROCESS_OF | 124 | 126 | preserve | 58-97 | 89-97 | T5 | muscle glucose transport activity | OrganOrTissueFunction | 58 | 97 | preserve | 140-177 | 173-177 | T9 | spontaneously hypertensive rats | Mammal | 140 | 177 | A8 | Training in swimming reduces blood pressure and increases muscle glucose transport activity as well as GLUT4 contents in stroke-prone spontaneously hypertensive rats. | 0-178 | 0 | 178 | Training in swimming reduces blood pressure and increases @SUBJECT$ as well as GLUT4 contents @PREDICAT$ stroke-prone @OBJECT$ . |
Fact | preserve | 497-499 | 497-499 | T35 | in | PROCESS_OF | 497 | 499 | preserve | 453-473 | 461-473 | T28 | genetic hypertension | DiseaseOrSyndrome | 453 | 473 | preserve | 500-505 | 500-505 | T32 | SHRSP | Mammal | 500 | 505 | A9 | We studied the relationship between genetic hypertension and insulin resistance in SHRSP and Wistar Kyoto rats (WKY) as a control. | 411-553 | 411 | 553 | We studied the relationship between @SUBJECT$ and insulin resistance @PREDICAT$ @OBJECT$ and Wistar Kyoto rats (WKY) as a control. |
Fact | preserve | 497-499 | 497-499 | T35 | in | PROCESS_OF | 497 | 499 | preserve | 478-496 | 486-496 | T29 | insulin resistance | PathologicFunction | 478 | 496 | preserve | 516-533 | 529-533 | T33 | Wistar Kyoto rats | Mammal | 516 | 533 | A10 | We studied the relationship between genetic hypertension and insulin resistance in SHRSP and Wistar Kyoto rats (WKY) as a control. | 411-553 | 411 | 553 | We studied the relationship between genetic hypertension and @SUBJECT$ @PREDICAT$ SHRSP and @OBJECT$ (WKY) as a control. |
Fact | preserve | 985-987 | 985-987 | T65 | in | LOCATION_OF | 985 | 987 | preserve | 988-993 | 988-993 | T63 | SHRSP | Mammal | 988 | 993 | preserve | 949-962 | 955-962 | T59 | GLUT4 protein | AminoAcidPeptideOrProtein | 949 | 962 | A11 | The swimming training also resulted in an approximately 20% increase in the insulin-stimulated glucose transport activity (p < 0.05) of soleus muscle strips and an approximately 3-fold increase in the plasma membrane GLUT4 protein expression (p < 0.01) in SHRSP. | 712-994 | 712 | 994 | The swimming training also resulted in an approximately 20% increase in the insulin-stimulated glucose transport activity (p < 0.05) of soleus muscle strips and an approximately 3-fold increase in the plasma membrane @OBJECT$ expression (p < 0.01) @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 65-97 | 89-97 | T11 | glucose transport activity | PROCESS_OF | 65 | 97 | preserve | 65-88 | 79-88 | T4 | glucose transport | CellFunction | 65 | 88 | preserve | 58-97 | 89-97 | T5 | muscle glucose transport activity | OrganOrTissueFunction | 58 | 97 | A12 | Training in swimming reduces blood pressure and increases muscle glucose transport activity as well as GLUT4 contents in stroke-prone spontaneously hypertensive rats. | 0-178 | 0 | 178 | Training in swimming reduces blood pressure and increases @OBJECT$ @SUBJECT$ @PREDICAT$ as well as GLUT4 contents in stroke-prone spontaneously hypertensive rats. |
Fact | preserve | 497-499 | 497-499 | T35 | in | PROCESS_OF | 497 | 499 | preserve | 478-496 | 486-496 | T29 | insulin resistance | PathologicFunction | 478 | 496 | preserve | 500-505 | 500-505 | T32 | SHRSP | Mammal | 500 | 505 | A13 | We studied the relationship between genetic hypertension and insulin resistance in SHRSP and Wistar Kyoto rats (WKY) as a control. | 411-553 | 411 | 553 | We studied the relationship between genetic hypertension and @SUBJECT$ @PREDICAT$ @OBJECT$ and Wistar Kyoto rats (WKY) as a control. |
Uncommitted | preserve | 800-803 | 800-803 | T49 | for | TREATS | 800 | 803 | preserve | 759-773 | 763-773 | T39 | ACE inhibitors | PharmacologicSubstance | 759 | 773 | preserve | 831-852 | 842-852 | T41 | myocardial infarction | DiseaseOrSyndrome | 831 | 852 | A1 | We conclude that ACE inhibitors are underprescribed for patients who experienced a myocardial infarction, illustrating the gap between clinical research and clinical practice, and the need for programs to ensure optimal medical management. | 742-999 | 742 | 999 | We conclude that @SUBJECT$ are underprescribed @PREDICAT$ patients who experienced a @OBJECT$ , illustrating the gap between clinical research and clinical practice, and the need for programs to ensure optimal medical management. |
Fact | preserve | 341-343 | 341-343 | T22 | in | TREATS | 341 | 343 | preserve | 315-327 | 320-327 | T16 | drug therapy | TherapeuticOrPreventiveProcedure | 315 | 327 | preserve | 348-356 | 348-356 | T18 | patients | PatientOrDisabledGroup | 348 | 356 | A2 | We retrospectively reviewed drug therapy at discharge in 534 patients to assess prescription of ACE inhibitor therapy, including dosage. | 281-429 | 281 | 429 | We retrospectively reviewed @SUBJECT$ at discharge @PREDICAT$ 534 @OBJECT$ to assess prescription of ACE inhibitor therapy, including dosage. |
Fact | preserve | 817-828 | 817-828 | T50 | experienced | PROCESS_OF | 817 | 828 | preserve | 831-852 | 842-852 | T41 | myocardial infarction | DiseaseOrSyndrome | 831 | 852 | preserve | 804-812 | 804-812 | T40 | patients | PatientOrDisabledGroup | 804 | 812 | A3 | We conclude that ACE inhibitors are underprescribed for patients who experienced a myocardial infarction, illustrating the gap between clinical research and clinical practice, and the need for programs to ensure optimal medical management. | 742-999 | 742 | 999 | We conclude that ACE inhibitors are underprescribed for @OBJECT$ who @PREDICAT$ a @SUBJECT$ , illustrating the gap between clinical research and clinical practice, and the need for programs to ensure optimal medical management. |
Uncommitted | preserve | 800-803 | 800-803 | T49 | for | TREATS | 800 | 803 | preserve | 759-773 | 763-773 | T39 | ACE inhibitors | PharmacologicSubstance | 759 | 773 | preserve | 804-812 | 804-812 | T40 | patients | PatientOrDisabledGroup | 804 | 812 | A4 | We conclude that ACE inhibitors are underprescribed for patients who experienced a myocardial infarction, illustrating the gap between clinical research and clinical practice, and the need for programs to ensure optimal medical management. | 742-999 | 742 | 999 | We conclude that @SUBJECT$ are underprescribed @PREDICAT$ @OBJECT$ who experienced a myocardial infarction, illustrating the gap between clinical research and clinical practice, and the need for programs to ensure optimal medical management. |
Fact | preserve | 197-208 | 197-208 | T13 | experienced | PROCESS_OF | 197 | 208 | preserve | 217-238 | 228-238 | T10 | myocardial infarction | DiseaseOrSyndrome | 217 | 238 | preserve | 184-192 | 184-192 | T9 | patients | PatientOrDisabledGroup | 184 | 192 | A5 | We attempted to determine physician prescribing patterns of angiotensin-converting enzyme (ACE) inhibitors in patients who experienced a myocardial infarction, stratified by left ventricular function. | 68-280 | 68 | 280 | We attempted to determine physician prescribing patterns of angiotensin-converting enzyme (ACE) inhibitors in @OBJECT$ who @PREDICAT$ a @SUBJECT$ , stratified by left ventricular function. |
Fact | preserve | 181-183 | 181-183 | T12 | in | TREATS | 181 | 183 | preserve | 134-180 | 170-180 | T8 | angiotensin-converting enzyme (ACE) inhibitors | PharmacologicSubstance | 134 | 180 | preserve | 184-192 | 184-192 | T9 | patients | PatientOrDisabledGroup | 184 | 192 | A6 | We attempted to determine physician prescribing patterns of angiotensin-converting enzyme (ACE) inhibitors in patients who experienced a myocardial infarction, stratified by left ventricular function. | 68-280 | 68 | 280 | We attempted to determine physician prescribing patterns of @SUBJECT$ @PREDICAT$ @OBJECT$ who experienced a myocardial infarction, stratified by left ventricular function. |
Fact | preserve | 181-183 | 181-183 | T12 | in | TREATS | 181 | 183 | preserve | 134-180 | 170-180 | T8 | angiotensin-converting enzyme (ACE) inhibitors | PharmacologicSubstance | 134 | 180 | preserve | 217-238 | 228-238 | T10 | myocardial infarction | DiseaseOrSyndrome | 217 | 238 | A7 | We attempted to determine physician prescribing patterns of angiotensin-converting enzyme (ACE) inhibitors in patients who experienced a myocardial infarction, stratified by left ventricular function. | 68-280 | 68 | 280 | We attempted to determine physician prescribing patterns of @SUBJECT$ @PREDICAT$ patients who experienced a @OBJECT$ , stratified by left ventricular function. |
Fact | preserve | 599-602 | 599-602 | T38 | for | TREATS | 599 | 602 | preserve | 566-571 | 566-571 | T28 | drugs | PharmacologicSubstance | 566 | 571 | preserve | 603-611 | 603-611 | T31 | patients | PatientOrDisabledGroup | 603 | 611 | A8 | The drugs were prescribed more often for patients who had an ejection fraction below 40% than for those with an ejection fraction of 40% or above (54% vs 28%, p<0.05). | 562-741 | 562 | 741 | The @SUBJECT$ were prescribed more often @PREDICAT$ @OBJECT$ who had an ejection fraction below 40% than for those with an ejection fraction of 40% or above (54% vs 28%, p<0.05). |
Fact | preserve | 2344-2353 | 2344-2353 | T135 | treatment | TREATS | 2,344 | 2,353 | preserve | 2305-2316 | 2305-2316 | T129 | pramipexole | OrganicChemical | 2,305 | 2,316 | preserve | 2358-2366 | 2358-2366 | T132 | patients | PatientOrDisabledGroup | 2,358 | 2,366 | A1 | CONCLUSIONS: Subject to the inherent limitations of modelling chronic disease progression and subsequent healthcare costs and patient utility, the results suggested that pramipexole was a cost effective treatment for patients with early and advanced PD in the US. | 2123-2404 | 2,123 | 2,404 | CONCLUSIONS: Subject to the inherent limitations of modelling chronic disease progression and subsequent healthcare costs and patient utility, the results suggested that @SUBJECT$ was a cost effective @PREDICAT$ for @OBJECT$ with early and advanced PD in the US. |
Counterfact | preserve | 1381-1410 | 1403-1410 | T80 | pramipexole treatment regimen | USES | 1,381 | 1,410 | preserve | 1393-1410 | 1403-1410 | T76 | treatment regimen | ResearchActivity | 1,393 | 1,410 | preserve | 1381-1392 | 1381-1392 | T75 | pramipexole | OrganicChemical | 1,381 | 1,392 | A2 | We also performed extensive sensitivity analyses by adding other dopamine agonists to the no-pramipexole treatment regimen and varying disease progression parameters. | 1282-1460 | 1,282 | 1,460 | We also performed extensive sensitivity analyses by adding other dopamine agonists to the no- @OBJECT$ @PREDICAT$ @SUBJECT$ and varying disease progression parameters. |
Fact | preserve | 1806-1810 | 1806-1810 | T99 | than | compared_with | 1,806 | 1,810 | preserve | 1754-1765 | 1754-1765 | T92 | pramipexole | OrganicChemical | 1,754 | 1,765 | preserve | 1820-1829 | 1820-1829 | T97 | treatment | TherapeuticOrPreventiveProcedure | 1,820 | 1,829 | A3 | MAIN OUTCOME MEASURES AND RESULTS: For patients with both early and advanced PD, treatment with pramipexole had higher costs but was more effective than baseline treatment. | 1646-1830 | 1,646 | 1,830 | MAIN OUTCOME MEASURES AND RESULTS: For patients with both early and advanced PD, treatment with @SUBJECT$ had higher costs but was more effective @PREDICAT$ baseline @OBJECT$ . |
Fact | preserve | 1749-1753 | 1749-1753 | T101 | with | USES | 1,749 | 1,753 | preserve | 1733-1742 | 1733-1742 | T91 | treatment | TherapeuticOrPreventiveProcedure | 1,733 | 1,742 | preserve | 1754-1765 | 1754-1765 | T92 | pramipexole | OrganicChemical | 1,754 | 1,765 | A5 | MAIN OUTCOME MEASURES AND RESULTS: For patients with both early and advanced PD, treatment with pramipexole had higher costs but was more effective than baseline treatment. | 1646-1830 | 1,646 | 1,830 | MAIN OUTCOME MEASURES AND RESULTS: For patients with both early and advanced PD, @SUBJECT$ @PREDICAT$ @OBJECT$ had higher costs but was more effective than baseline treatment. |
Fact | preserve | 534-543 | 534-543 | T30 | treatment | TREATS | 534 | 543 | preserve | 499-510 | 499-510 | T24 | pramipexole | OrganicChemical | 499 | 510 | preserve | 547-555 | 547-555 | T27 | patients | PatientOrDisabledGroup | 547 | 555 | A7 | The aim of this study was to estimate the costs and cost effectiveness (cost utility) of pramipexole compared with baseline treatment in patients with early and advanced PD. | 398-589 | 398 | 589 | The aim of this study was to estimate the costs and cost effectiveness (cost utility) of @SUBJECT$ compared with baseline @PREDICAT$ in @OBJECT$ with early and advanced PD. |
Fact | preserve | 127-136 | 127-136 | T10 | treatment | TREATS | 127 | 136 | preserve | 79-90 | 79-90 | T5 | Pramipexole | OrganicChemical | 79 | 90 | preserve | 150-158 | 150-158 | T8 | symptoms | SignOrSymptom | 150 | 158 | A8 | OBJECTIVE: Pramipexole was recently approved in the US for treatment of the symptoms of idiopathic Parkinson's disease (PD). | 68-198 | 68 | 198 | OBJECTIVE: @SUBJECT$ was recently approved in the US for @PREDICAT$ of the @OBJECT$ of idiopathic Parkinson's disease (PD). |
Fact | preserve | 2305-2353 | 2344-2353 | T134 | pramipexole was a cost effective treatment | ISA | 2,305 | 2,353 | preserve | 2305-2316 | 2305-2316 | T129 | pramipexole | OrganicChemical | 2,305 | 2,316 | preserve | 2344-2353 | 2344-2353 | T131 | treatment | TherapeuticOrPreventiveProcedure | 2,344 | 2,353 | A9 | CONCLUSIONS: Subject to the inherent limitations of modelling chronic disease progression and subsequent healthcare costs and patient utility, the results suggested that pramipexole was a cost effective treatment for patients with early and advanced PD in the US. | 2123-2404 | 2,123 | 2,404 | CONCLUSIONS: Subject to the inherent limitations of modelling chronic disease progression and subsequent healthcare costs and patient utility, the results suggested that @SUBJECT$ @PREDICAT$ @OBJECT$ for patients with early and advanced PD in the US. |
Fact | preserve | 34-36 | 34-36 | T4 | in | TREATS | 34 | 36 | preserve | 22-33 | 22-33 | T2 | pramipexole | OrganicChemical | 22 | 33 | preserve | 37-56 | 49-56 | T3 | Parkinson's disease | DiseaseOrSyndrome | 37 | 56 | A10 | Cost effectiveness of pramipexole in Parkinson's disease in the US. | 0-67 | 0 | 67 | Cost effectiveness of @SUBJECT$ @PREDICAT$ @OBJECT$ in the US. |
Fact | preserve | 273-281 | 273-281 | T19 | compared | compared_with | 273 | 281 | preserve | 208-219 | 208-219 | T11 | pramipexole | OrganicChemical | 208 | 219 | preserve | 287-294 | 287-294 | T12 | placebo | MedicalDevice | 287 | 294 | A11 | Although pramipexole has been found to be safe and efficacious when compared with placebo, little data are yet available on its cost effectiveness when compared with baseline treatment. | 199-397 | 199 | 397 | Although @SUBJECT$ has been found to be safe and efficacious when @PREDICAT$ with @OBJECT$ , little data are yet available on its cost effectiveness when compared with baseline treatment. |
Fact | preserve | 1806-1810 | 1806-1810 | T100 | than | higher_than | 1,806 | 1,810 | preserve | 1754-1765 | 1754-1765 | T92 | pramipexole | OrganicChemical | 1,754 | 1,765 | preserve | 1820-1829 | 1820-1829 | T97 | treatment | TherapeuticOrPreventiveProcedure | 1,820 | 1,829 | A12 | MAIN OUTCOME MEASURES AND RESULTS: For patients with both early and advanced PD, treatment with pramipexole had higher costs but was more effective than baseline treatment. | 1646-1830 | 1,646 | 1,830 | MAIN OUTCOME MEASURES AND RESULTS: For patients with both early and advanced PD, treatment with @SUBJECT$ had higher costs but was more effective @PREDICAT$ baseline @OBJECT$ . |
Fact | preserve | 511-519 | 511-519 | T29 | compared | compared_with | 511 | 519 | preserve | 499-510 | 499-510 | T24 | pramipexole | OrganicChemical | 499 | 510 | preserve | 534-543 | 534-543 | T26 | treatment | TherapeuticOrPreventiveProcedure | 534 | 543 | A13 | The aim of this study was to estimate the costs and cost effectiveness (cost utility) of pramipexole compared with baseline treatment in patients with early and advanced PD. | 398-589 | 398 | 589 | The aim of this study was to estimate the costs and cost effectiveness (cost utility) of @SUBJECT$ @PREDICAT$ with baseline @OBJECT$ in patients with early and advanced PD. |
Fact | preserve | 1922-1931 | 1922-1931 | T108 | treatment | TREATS | 1,922 | 1,931 | preserve | 1986-1991 | 1986-1991 | T101 | 4-OHA | TherapeuticOrPreventiveProcedure | 1,986 | 1,991 | preserve | 1955-1963 | 1955-1963 | T98 | patients | PatientOrDisabledGroup | 1,955 | 1,963 | A2 | CONCLUSION: The treatment of premenopausal patients with triptorelin plus 4-OHA is feasible and leads to a much greater inhibition of main circulating estrogens than treatment with the analog alone. | 1906-2122 | 1,906 | 2,122 | CONCLUSION: The @PREDICAT$ of premenopausal @OBJECT$ with triptorelin plus @SUBJECT$ is feasible and leads to a much greater inhibition of main circulating estrogens than treatment with the analog alone. |
Fact | preserve | 560-590 | 580-590 | T43 | aromatase inhibitor formestane | ISA | 560 | 590 | preserve | 580-590 | 580-590 | T36 | formestane | OrganicChemical | 580 | 590 | preserve | 560-579 | 570-579 | T35 | aromatase inhibitor | PharmacologicSubstance | 560 | 579 | A3 | monthly; n = 10) alone or in combination with the aromatase inhibitor formestane (4-OHA, 500 mg i.m. | 504-616 | 504 | 616 | monthly; n = 10) alone or in combination with the @OBJECT$ @PREDICAT$ @SUBJECT$ (4-OHA, 500 mg i.m. |
Fact | preserve | 400-404 | 400-404 | T44 | with | PROCESS_OF | 400 | 404 | preserve | 414-427 | 421-427 | T29 | breast cancer | NeoplasticProcess | 414 | 427 | preserve | 394-399 | 394-399 | T28 | women | PopulationGroup | 394 | 399 | A4 | MATERIAL AND METHODS: Twenty-one premenopausal women with advanced breast cancer were randomised to receive the GnRH analog triptorelin (3.75 mg i.m. | 347-503 | 347 | 503 | MATERIAL AND METHODS: Twenty-one premenopausal @OBJECT$ @PREDICAT$ advanced @SUBJECT$ were randomised to receive the GnRH analog triptorelin (3.75 mg i.m. |
Fact | preserve | 37-44 | 37-44 | T9 | treated | TREATS | 37 | 44 | preserve | 52-95 | 89-95 | T4 | gonadotropin-releasing hormone analog | AminoAcidPeptideOrProtein | 52 | 95 | preserve | 28-36 | 28-36 | T3 | patients | PatientOrDisabledGroup | 28 | 36 | A9 | Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. | 0-185 | 0 | 185 | Premenopausal breast cancer @OBJECT$ @PREDICAT$ with a @SUBJECT$ alone or in combination with an aromatase inhibitor: a comparative endocrine study. |
Fact | preserve | 14-36 | 28-36 | T8 | breast cancer patients | PROCESS_OF | 14 | 36 | preserve | 14-27 | 21-27 | T2 | breast cancer | NeoplasticProcess | 14 | 27 | preserve | 28-36 | 28-36 | T3 | patients | PatientOrDisabledGroup | 28 | 36 | A11 | Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. | 0-185 | 0 | 185 | Premenopausal @SUBJECT$ @PREDICAT$ @OBJECT$ treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. |
Fact | preserve | 323-345 | 337-345 | T19 | breast cancer patients | PROCESS_OF | 323 | 345 | preserve | 323-336 | 330-336 | T17 | breast cancer | NeoplasticProcess | 323 | 336 | preserve | 337-345 | 337-345 | T18 | patients | PatientOrDisabledGroup | 337 | 345 | A13 | BACKGROUND: The combination of a GnRH analogue and an aromatase inhibitor can induce a complete estrogen blockade in premenopausal breast cancer patients. | 186-346 | 186 | 346 | BACKGROUND: The combination of a GnRH analogue and an aromatase inhibitor can induce a complete estrogen blockade in premenopausal @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 454-461 | 454-461 | T45 | receive | ADMINISTERED_TO | 454 | 461 | preserve | 466-470 | 466-470 | T30 | GnRH | AminoAcidPeptideOrProtein | 466 | 470 | preserve | 394-399 | 394-399 | T28 | women | PopulationGroup | 394 | 399 | A14 | MATERIAL AND METHODS: Twenty-one premenopausal women with advanced breast cancer were randomised to receive the GnRH analog triptorelin (3.75 mg i.m. | 347-503 | 347 | 503 | MATERIAL AND METHODS: Twenty-one premenopausal @OBJECT$ with advanced breast cancer were randomised to @PREDICAT$ the @SUBJECT$ analog triptorelin (3.75 mg i.m. |
Fact | preserve | 1757-1765 | 1757-1765 | T98 | compared | compared_with | 1,757 | 1,765 | preserve | 1487-1494 | 1487-1494 | T85 | therapy | TherapeuticOrPreventiveProcedure | 1,487 | 1,494 | preserve | 1777-1784 | 1777-1784 | T97 | placebo | MedicalDevice | 1,777 | 1,784 | A2 | 16), pulmonary artery diastolic pressure (-4.7 mm Hg; P=0.013), and systolic blood pressure (-6.8 mm Hg; P=0.013) were observed in the valsartan 160 mg group compared with placebo. | 1587-1785 | 1,587 | 1,785 | 16), pulmonary artery diastolic pressure (-4.7 mm Hg; P=0.013), and systolic blood pressure @SUBJECT$ -6.8 mm Hg; P=0.013) were observed in the valsartan 160 mg group @PREDICAT$ with @OBJECT$ . |
Fact | preserve | 563-567 | 563-567 | T47 | with | PROCESS_OF | 563 | 567 | preserve | 568-589 | 582-589 | T35 | chronic heart failure | DiseaseOrSyndrome | 568 | 589 | preserve | 554-562 | 554-562 | T34 | patients | PatientOrDisabledGroup | 554 | 562 | A3 | METHODS AND RESULTS: Eighty-three symptomatic stable patients with chronic heart failure receiving long-term ACE inhibitor therapy were randomly assigned to double-blind treatment with valsartan 80 mg BID, valsartan 160 mg BID, or placebo while receiving their usual ACE inhibitor therapy. | 495-809 | 495 | 809 | METHODS AND RESULTS: Eighty-three symptomatic stable @OBJECT$ @PREDICAT$ @SUBJECT$ receiving long-term ACE inhibitor therapy were randomly assigned to double-blind treatment with valsartan 80 mg BID, valsartan 160 mg BID, or placebo while receiving their usual ACE inhibitor therapy. |
Fact | preserve | 596-605 | 596-605 | T48 | receiving | ADMINISTERED_TO | 596 | 605 | preserve | 630-637 | 630-637 | T38 | therapy | TherapeuticOrPreventiveProcedure | 630 | 637 | preserve | 554-562 | 554-562 | T34 | patients | PatientOrDisabledGroup | 554 | 562 | A4 | METHODS AND RESULTS: Eighty-three symptomatic stable patients with chronic heart failure receiving long-term ACE inhibitor therapy were randomly assigned to double-blind treatment with valsartan 80 mg BID, valsartan 160 mg BID, or placebo while receiving their usual ACE inhibitor therapy. | 495-809 | 495 | 809 | METHODS AND RESULTS: Eighty-three symptomatic stable @OBJECT$ with chronic heart failure @PREDICAT$ long-term ACE inhibitor @SUBJECT$ were randomly assigned to double-blind treatment with valsartan 80 mg BID, valsartan 160 mg BID, or placebo while receiving their usual ACE inhibitor therapy. |
Fact | preserve | 765-774 | 765-774 | T50 | receiving | ADMINISTERED_TO | 765 | 774 | preserve | 801-808 | 801-808 | T46 | therapy | TherapeuticOrPreventiveProcedure | 801 | 808 | preserve | 554-562 | 554-562 | T34 | patients | PatientOrDisabledGroup | 554 | 562 | A5 | METHODS AND RESULTS: Eighty-three symptomatic stable patients with chronic heart failure receiving long-term ACE inhibitor therapy were randomly assigned to double-blind treatment with valsartan 80 mg BID, valsartan 160 mg BID, or placebo while receiving their usual ACE inhibitor therapy. | 495-809 | 495 | 809 | METHODS AND RESULTS: Eighty-three symptomatic stable @OBJECT$ with chronic heart failure receiving long-term ACE inhibitor therapy were randomly assigned to double-blind treatment with valsartan 80 mg BID, valsartan 160 mg BID, or placebo while @PREDICAT$ their usual ACE inhibitor @SUBJECT$ . |
Fact | preserve | 306-314 | 306-314 | T22 | suppress | INHIBITS | 306 | 314 | preserve | 272-286 | 276-286 | T16 | ACE inhibitors | PharmacologicSubstance | 272 | 286 | preserve | 343-357 | 343-354 | T19 | angiotensin II | AminoAcidPeptideOrProtein | 343 | 357 | A6 | BACKGROUND: ACE inhibitors may not adequately suppress deleterious levels of angiotensin II in patients with heart failure. | 260-389 | 260 | 389 | BACKGROUND: @SUBJECT$ may not adequately @PREDICAT$ deleterious levels of @OBJECT$ in patients with heart failure. |
Fact | preserve | 370-374 | 370-374 | T24 | with | PROCESS_OF | 370 | 374 | preserve | 375-388 | 381-388 | T21 | heart failure | DiseaseOrSyndrome | 375 | 388 | preserve | 361-369 | 361-369 | T20 | patients | PatientOrDisabledGroup | 361 | 369 | A8 | BACKGROUND: ACE inhibitors may not adequately suppress deleterious levels of angiotensin II in patients with heart failure. | 260-389 | 260 | 389 | BACKGROUND: ACE inhibitors may not adequately suppress deleterious levels of angiotensin II in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 180-184 | 180-184 | T11 | with | PROCESS_OF | 180 | 184 | preserve | 185-198 | 191-198 | T9 | heart failure | DiseaseOrSyndrome | 185 | 198 | preserve | 171-179 | 171-179 | T8 | patients | PatientOrDisabledGroup | 171 | 179 | A9 | Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. | 0-199 | 0 | 199 | Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 787-808 | 801-808 | T51 | ACE inhibitor therapy | USES | 787 | 808 | preserve | 801-808 | 801-808 | T46 | therapy | TherapeuticOrPreventiveProcedure | 801 | 808 | preserve | 787-800 | 791-800 | T45 | ACE inhibitor | PharmacologicSubstance | 787 | 800 | A10 | METHODS AND RESULTS: Eighty-three symptomatic stable patients with chronic heart failure receiving long-term ACE inhibitor therapy were randomly assigned to double-blind treatment with valsartan 80 mg BID, valsartan 160 mg BID, or placebo while receiving their usual ACE inhibitor therapy. | 495-809 | 495 | 809 | METHODS AND RESULTS: Eighty-three symptomatic stable patients with chronic heart failure receiving long-term ACE inhibitor therapy were randomly assigned to double-blind treatment with valsartan 80 mg BID, valsartan 160 mg BID, or placebo while receiving their usual @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 616-637 | 630-637 | T49 | ACE inhibitor therapy | USES | 616 | 637 | preserve | 630-637 | 630-637 | T38 | therapy | TherapeuticOrPreventiveProcedure | 630 | 637 | preserve | 616-629 | 620-629 | T37 | ACE inhibitor | PharmacologicSubstance | 616 | 629 | A14 | METHODS AND RESULTS: Eighty-three symptomatic stable patients with chronic heart failure receiving long-term ACE inhibitor therapy were randomly assigned to double-blind treatment with valsartan 80 mg BID, valsartan 160 mg BID, or placebo while receiving their usual ACE inhibitor therapy. | 495-809 | 495 | 809 | METHODS AND RESULTS: Eighty-three symptomatic stable patients with chronic heart failure receiving long-term @OBJECT$ @PREDICAT$ @SUBJECT$ were randomly assigned to double-blind treatment with valsartan 80 mg BID, valsartan 160 mg BID, or placebo while receiving their usual ACE inhibitor therapy. |
Fact | preserve | 2213-2234 | 2227-2234 | T121 | ACE inhibitor therapy | USES | 2,213 | 2,234 | preserve | 2227-2234 | 2227-2234 | T120 | therapy | TherapeuticOrPreventiveProcedure | 2,227 | 2,234 | preserve | 2213-2226 | 2217-2226 | T119 | ACE inhibitor | PharmacologicSubstance | 2,213 | 2,226 | A16 | CONCLUSIONS: Physiologically active levels of angiotensin II persist during standard long-term ACE inhibitor therapy. | 2106-2235 | 2,106 | 2,235 | CONCLUSIONS: Physiologically active levels of angiotensin II persist during standard long-term @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 2041-2043 | 2041-2043 | T115 | in | TREATS | 2,041 | 2,043 | preserve | 2008-2012 | 2008-2012 | T110 | LARS | TherapeuticOrPreventiveProcedure | 2,008 | 2,012 | preserve | 2052-2060 | 2052-2060 | T113 | patients | PatientOrDisabledGroup | 2,052 | 2,060 | A1 | CONCLUSIONS: As shown in this study, LARS is safe and effective in elderly patients with GERD. | 1971-2071 | 1,971 | 2,071 | CONCLUSIONS: As shown in this study, @SUBJECT$ is safe and effective @PREDICAT$ elderly @OBJECT$ with GERD. |
Fact | preserve | 2061-2065 | 2061-2065 | T116 | with | PROCESS_OF | 2,061 | 2,065 | preserve | 2066-2070 | 2066-2070 | T114 | GERD | DiseaseOrSyndrome | 2,066 | 2,070 | preserve | 2052-2060 | 2052-2060 | T113 | patients | PatientOrDisabledGroup | 2,052 | 2,060 | A2 | CONCLUSIONS: As shown in this study, LARS is safe and effective in elderly patients with GERD. | 1971-2071 | 1,971 | 2,071 | CONCLUSIONS: As shown in this study, LARS is safe and effective in elderly @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 2170-2172 | 2170-2172 | T126 | in | PROCESS_OF | 2,170 | 2,172 | preserve | 2072-2075 | 2072-2075 | T118 | Age | OrganismAttribute | 2,072 | 2,075 | preserve | 2197-2205 | 2197-2205 | T125 | patients | PatientOrDisabledGroup | 2,197 | 2,205 | A3 | Age older than 65 years should not be a contraindication to laparoscopic antireflux surgery in properly selected patients. | 2072-2206 | 2,072 | 2,206 | @SUBJECT$ older than 65 years should not be a contraindication to laparoscopic antireflux surgery @PREDICAT$ properly selected @OBJECT$ . |
Fact | preserve | 557-560 | 557-560 | T33 | for | TREATS | 557 | 560 | preserve | 552-556 | 552-556 | T28 | LARS | TherapeuticOrPreventiveProcedure | 552 | 556 | preserve | 561-565 | 561-565 | T29 | GERD | DiseaseOrSyndrome | 561 | 565 | A4 | METHODS: All patients undergoing LARS for GERD at the Washington University Medical Center were entered prospectively into a computerized database. | 519-672 | 519 | 672 | METHODS: All patients undergoing @SUBJECT$ @PREDICAT$ @OBJECT$ at the Washington University Medical Center were entered prospectively into a computerized database. |
Fact | preserve | 1378-1386 | 1378-1386 | T83 | occurred | OCCURS_IN | 1,378 | 1,386 | preserve | 1364-1377 | 1364-1377 | T74 | complications | PathologicFunction | 1,364 | 1,377 | preserve | 1424-1431 | 1424-1431 | T76 | elderly | AgeGroup | 1,424 | 1,431 | A6 | Grade I complications occurred significantly more frequently in the elderly (13.9%) than in the nonelderly (2.6%), but the incidence of grade II complications was similar between the groups (elderly 2.8% vs nonelderly 2.7%). | 1350-1592 | 1,350 | 1,592 | Grade I @SUBJECT$ @PREDICAT$ significantly more frequently in the @OBJECT$ (13.9%) than in the nonelderly (2.6%), but the incidence of grade II complications was similar between the groups (elderly 2.8% vs nonelderly 2.7%). |
Fact | preserve | 35-38 | 35-38 | T5 | for | TREATS | 35 | 38 | preserve | 3-34 | 27-34 | T1 | laparoscopic antireflux surgery | TherapeuticOrPreventiveProcedure | 3 | 34 | preserve | 39-70 | 63-70 | T2 | gastroesophageal reflux disease | DiseaseOrSyndrome | 39 | 70 | A8 | Is laparoscopic antireflux surgery for gastroesophageal reflux disease in the elderly safe and effective? | 0-111 | 0 | 111 | Is @SUBJECT$ @PREDICAT$ @OBJECT$ in the elderly safe and effective? |
Fact | preserve | 457-459 | 457-459 | T25 | in | TREATS | 457 | 459 | preserve | 452-456 | 452-456 | T21 | LARS | TherapeuticOrPreventiveProcedure | 452 | 456 | preserve | 464-471 | 464-471 | T22 | elderly | AgeGroup | 464 | 471 | A9 | The purpose of this study was to determine if the results of LARS in the elderly are comparable with those in younger patients. | 385-518 | 385 | 518 | The purpose of this study was to determine if the results of @SUBJECT$ @PREDICAT$ the @OBJECT$ are comparable with those in younger patients. |
Fact | preserve | 2041-2043 | 2041-2043 | T115 | in | TREATS | 2,041 | 2,043 | preserve | 2008-2012 | 2008-2012 | T110 | LARS | TherapeuticOrPreventiveProcedure | 2,008 | 2,012 | preserve | 2066-2070 | 2066-2070 | T114 | GERD | DiseaseOrSyndrome | 2,066 | 2,070 | A10 | CONCLUSIONS: As shown in this study, LARS is safe and effective in elderly patients with GERD. | 1971-2071 | 1,971 | 2,071 | CONCLUSIONS: As shown in this study, @SUBJECT$ is safe and effective @PREDICAT$ elderly patients with @OBJECT$ . |
Fact | preserve | 724-733 | 724-733 | T45 | underwent | TREATS | 724 | 733 | preserve | 734-738 | 734-738 | T36 | LARS | TherapeuticOrPreventiveProcedure | 734 | 738 | preserve | 715-723 | 715-723 | T35 | patients | PatientOrDisabledGroup | 715 | 723 | A11 | Between May 1992 and June 1998, 339 patients underwent LARS and were divided into two groups based on age: nonelderly (ages, 18-64 years; n = 303) and elderly (age, >/=65 years; n = 36). | 673-877 | 673 | 877 | Between May 1992 and June 1998, 339 @OBJECT$ @PREDICAT$ @SUBJECT$ and were divided into two groups based on age: nonelderly (ages, 18-64 years; n = 303) and elderly (age, >/=65 years; n = 36). |
Possible | preserve | 1617-1621 | 1617-1621 | T82 | risk | PREDISPOSES | 1,617 | 1,621 | preserve | 1575-1582 | 1575-1582 | T77 | alcohol | OrganicChemical | 1,575 | 1,582 | preserve | 1649-1662 | 1656-1662 | T80 | breast cancer | NeoplasticProcess | 1,649 | 1,662 | A1 | These data suggest that alcohol may preferentially increase risk of ER-positive/PR-positive breast cancer in postmenopausal women. | 1551-1693 | 1,551 | 1,693 | These data suggest that @SUBJECT$ may preferentially increase @PREDICAT$ of ER-positive/PR-positive @OBJECT$ in postmenopausal women. |
Doubtful | preserve | 1092-1096 | 1092-1096 | T59 | risk | PREDISPOSES | 1,092 | 1,096 | preserve | 1026-1037 | 1034-1037 | T52 | Alcohol use | IndividualBehavior | 1,026 | 1,037 | preserve | 1100-1113 | 1107-1113 | T56 | breast cancer | NeoplasticProcess | 1,100 | 1,113 | A2 | Alcohol use was generally not associated with premenopausal risk of breast cancer, regardless of hormone-receptor status. | 1026-1153 | 1,026 | 1,153 | @SUBJECT$ was generally not associated with premenopausal @PREDICAT$ of @OBJECT$ , regardless of hormone-receptor status. |
Fact | preserve | 121-125 | 121-125 | T19 | risk | PREDISPOSES | 121 | 125 | preserve | 162-180 | 172-180 | T10 | oestrogen receptor | AminoAcidPeptideOrProtein | 162 | 180 | preserve | 129-142 | 136-142 | T8 | breast cancer | NeoplasticProcess | 129 | 142 | A3 | We examined the role of alcohol on the risk of breast cancer by the joint oestrogen receptor (ER) and progesterone receptor (PR) status of the tumour using data from two case-control studies conducted in Los Angeles County, USA. | 82-322 | 82 | 322 | We examined the role of alcohol on the @PREDICAT$ of @OBJECT$ by the joint @SUBJECT$ (ER) and progesterone receptor (PR) status of the tumour using data from two case-control studies conducted in Los Angeles County, USA. |
Fact | preserve | 1663-1665 | 1663-1665 | T83 | in | PROCESS_OF | 1,663 | 1,665 | preserve | 1649-1662 | 1656-1662 | T80 | breast cancer | NeoplasticProcess | 1,649 | 1,662 | preserve | 1687-1692 | 1687-1692 | T81 | women | PopulationGroup | 1,687 | 1,692 | A5 | These data suggest that alcohol may preferentially increase risk of ER-positive/PR-positive breast cancer in postmenopausal women. | 1551-1693 | 1,551 | 1,693 | These data suggest that alcohol may preferentially increase risk of ER-positive/PR-positive @SUBJECT$ @PREDICAT$ postmenopausal @OBJECT$ . |
Fact | preserve | 1025-1069 | 1059-1069 | T62 | montelukast (leukotriene receptor inhibitors | ISA | 1,025 | 1,069 | preserve | 1025-1036 | 1025-1036 | T55 | montelukast | OrganicChemical | 1,025 | 1,036 | preserve | 1038-1069 | 1059-1069 | T56 | leukotriene receptor inhibitors | OrganicChemical | 1,038 | 1,069 | A3 | But only two are used as a drugs: zafirlukast and montelukast (leukotriene receptor inhibitors) montelukast and zileuton (5-lipoxygenase inhibitors) having the best efficacy in asthma treatment. | 969-1181 | 969 | 1,181 | But only two are used as a drugs: zafirlukast and @SUBJECT$ @PREDICAT$ @OBJECT$ ) montelukast and zileuton (5-lipoxygenase inhibitors) having the best efficacy in asthma treatment. |
Fact | preserve | 1025-1069 | 1059-1069 | T62 | montelukast (leukotriene receptor inhibitors | ISA | 1,025 | 1,069 | preserve | 1009-1020 | 1009-1020 | T54 | zafirlukast | OrganicChemical | 1,009 | 1,020 | preserve | 1038-1069 | 1059-1069 | T56 | leukotriene receptor inhibitors | OrganicChemical | 1,038 | 1,069 | A4 | But only two are used as a drugs: zafirlukast and montelukast (leukotriene receptor inhibitors) montelukast and zileuton (5-lipoxygenase inhibitors) having the best efficacy in asthma treatment. | 969-1181 | 969 | 1,181 | But only two are used as a drugs: @SUBJECT$ and @PREDICAT$ @OBJECT$ ) montelukast and zileuton (5-lipoxygenase inhibitors) having the best efficacy in asthma treatment. |
Fact | preserve | 1483-1485 | 1483-1485 | T95 | in | TREATS | 1,483 | 1,485 | preserve | 1435-1446 | 1435-1446 | T84 | zafirlukast | OrganicChemical | 1,435 | 1,446 | preserve | 1503-1509 | 1503-1509 | T88 | asthma | DiseaseOrSyndrome | 1,503 | 1,509 | A5 | It has been proved that zafirlukast and zileuton show the high efficacy in mild-to-moderate asthma, exercise-induced asthma, allergen-induced asthma and aspirin-induced asthma. | 1405-1594 | 1,405 | 1,594 | It has been proved that @SUBJECT$ and zileuton show the high efficacy @PREDICAT$ mild-to-moderate @OBJECT$ , exercise-induced asthma, allergen-induced asthma and aspirin-induced asthma. |
Fact | preserve | 1171-1180 | 1171-1180 | T65 | treatment | TREATS | 1,171 | 1,180 | preserve | 1103-1128 | 1118-1128 | T59 | 5-lipoxygenase inhibitors | PharmacologicSubstance | 1,103 | 1,128 | preserve | 1158-1164 | 1158-1164 | T60 | asthma | DiseaseOrSyndrome | 1,158 | 1,164 | A7 | But only two are used as a drugs: zafirlukast and montelukast (leukotriene receptor inhibitors) montelukast and zileuton (5-lipoxygenase inhibitors) having the best efficacy in asthma treatment. | 969-1181 | 969 | 1,181 | But only two are used as a drugs: zafirlukast and montelukast (leukotriene receptor inhibitors) montelukast and zileuton ( @SUBJECT$ ) having the best efficacy in @OBJECT$ @PREDICAT$ . |
Fact | preserve | 1503-1541 | 1503-1509 | T97 | asthma, exercise-induced asthma | TREATS | 1,503 | 1,541 | preserve | 1451-1459 | 1451-1459 | T85 | zileuton | OrganicChemical | 1,451 | 1,459 | preserve | 1518-1541 | 1535-1541 | T89 | exercise-induced asthma | DiseaseOrSyndrome | 1,518 | 1,541 | A8 | It has been proved that zafirlukast and zileuton show the high efficacy in mild-to-moderate asthma, exercise-induced asthma, allergen-induced asthma and aspirin-induced asthma. | 1405-1594 | 1,405 | 1,594 | It has been proved that zafirlukast and @SUBJECT$ show the high efficacy in mild-to-moderate @PREDICAT$ @OBJECT$ , allergen-induced asthma and aspirin-induced asthma. |
Fact | preserve | 851-853 | 851-853 | T47 | on | LOCATION_OF | 851 | 853 | preserve | 858-870 | 863-870 | T45 | cell surface | CellComponent | 858 | 870 | preserve | 813-850 | 841-850 | T44 | cysteinyl leukotriene receptors | AminoAcidPeptideOrProtein | 813 | 850 | A9 | They can block the 5-lipoxygenase enzyme and/or 5-lipoxygenase-activating-proteine (FLAP), or can block the cysteinyl leukotriene receptors on the cell surface. | 699-871 | 699 | 871 | They can block the 5-lipoxygenase enzyme and/or 5-lipoxygenase-activating-proteine (FLAP), or can block the @OBJECT$ @PREDICAT$ the @SUBJECT$ . |
Fact | preserve | 101-110 | 101-110 | T6 | treatment | TREATS | 101 | 110 | preserve | 12-44 | 33-44 | T2 | leukotriene receptor antagonists | OrganicChemical | 12 | 44 | preserve | 84-100 | 94-100 | T4 | bronchial asthma | DiseaseOrSyndrome | 84 | 100 | A11 | [The use of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in bronchial asthma treatment]. | 0-112 | 0 | 112 | [The use of @SUBJECT$ and 5-lipoxygenase inhibitors in @OBJECT$ @PREDICAT$ ]. |
Fact | preserve | 1093-1128 | 1118-1128 | T66 | zileuton (5-lipoxygenase inhibitors | TREATS | 1,093 | 1,128 | preserve | 1093-1101 | 1093-1101 | T58 | zileuton | OrganicChemical | 1,093 | 1,101 | preserve | 1158-1164 | 1158-1164 | T60 | asthma | DiseaseOrSyndrome | 1,158 | 1,164 | A12 | But only two are used as a drugs: zafirlukast and montelukast (leukotriene receptor inhibitors) montelukast and zileuton (5-lipoxygenase inhibitors) having the best efficacy in asthma treatment. | 969-1181 | 969 | 1,181 | But only two are used as a drugs: zafirlukast and montelukast (leukotriene receptor inhibitors) montelukast and @SUBJECT$ @PREDICAT$ ) having the best efficacy in @OBJECT$ treatment. |
Fact | preserve | 101-110 | 101-110 | T6 | treatment | TREATS | 101 | 110 | preserve | 49-74 | 64-74 | T3 | 5-lipoxygenase inhibitors | PharmacologicSubstance | 49 | 74 | preserve | 84-100 | 94-100 | T4 | bronchial asthma | DiseaseOrSyndrome | 84 | 100 | A13 | [The use of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in bronchial asthma treatment]. | 0-112 | 0 | 112 | [The use of leukotriene receptor antagonists and @SUBJECT$ in @OBJECT$ @PREDICAT$ ]. |
Fact | preserve | 1200-1204 | 1200-1204 | T83 | with | USES | 1,200 | 1,204 | preserve | 1190-1199 | 1190-1199 | T68 | treatment | TherapeuticOrPreventiveProcedure | 1,190 | 1,199 | preserve | 1211-1216 | 1211-1216 | T69 | drugs | PharmacologicSubstance | 1,211 | 1,216 | A14 | Chronic treatment with these drugs results in a decrease of asthmatic symptoms, improvement of lung function (FEV1, PEF) and decreased usage of other medications--beta-adrenergic agonists and inhaled steroids. | 1182-1404 | 1,182 | 1,404 | Chronic @SUBJECT$ @PREDICAT$ these @OBJECT$ results in a decrease of asthmatic symptoms, improvement of lung function (FEV1, PEF) and decreased usage of other medications--beta-adrenergic agonists and inhaled steroids. |
Fact | preserve | 1093-1128 | 1118-1128 | T64 | zileuton (5-lipoxygenase inhibitors | ISA | 1,093 | 1,128 | preserve | 1093-1101 | 1093-1101 | T58 | zileuton | OrganicChemical | 1,093 | 1,101 | preserve | 1103-1128 | 1118-1128 | T59 | 5-lipoxygenase inhibitors | PharmacologicSubstance | 1,103 | 1,128 | A16 | But only two are used as a drugs: zafirlukast and montelukast (leukotriene receptor inhibitors) montelukast and zileuton (5-lipoxygenase inhibitors) having the best efficacy in asthma treatment. | 969-1181 | 969 | 1,181 | But only two are used as a drugs: zafirlukast and montelukast (leukotriene receptor inhibitors) montelukast and @SUBJECT$ @PREDICAT$ @OBJECT$ ) having the best efficacy in asthma treatment. |
Fact | preserve | 1503-1541 | 1503-1509 | T97 | asthma, exercise-induced asthma | TREATS | 1,503 | 1,541 | preserve | 1435-1446 | 1435-1446 | T84 | zafirlukast | OrganicChemical | 1,435 | 1,446 | preserve | 1518-1541 | 1535-1541 | T89 | exercise-induced asthma | DiseaseOrSyndrome | 1,518 | 1,541 | A18 | It has been proved that zafirlukast and zileuton show the high efficacy in mild-to-moderate asthma, exercise-induced asthma, allergen-induced asthma and aspirin-induced asthma. | 1405-1594 | 1,405 | 1,594 | It has been proved that @SUBJECT$ and zileuton show the high efficacy in mild-to-moderate @PREDICAT$ @OBJECT$ , allergen-induced asthma and aspirin-induced asthma. |
Fact | preserve | 1483-1485 | 1483-1485 | T95 | in | TREATS | 1,483 | 1,485 | preserve | 1451-1459 | 1451-1459 | T85 | zileuton | OrganicChemical | 1,451 | 1,459 | preserve | 1503-1509 | 1503-1509 | T88 | asthma | DiseaseOrSyndrome | 1,503 | 1,509 | A19 | It has been proved that zafirlukast and zileuton show the high efficacy in mild-to-moderate asthma, exercise-induced asthma, allergen-induced asthma and aspirin-induced asthma. | 1405-1594 | 1,405 | 1,594 | It has been proved that zafirlukast and @SUBJECT$ show the high efficacy @PREDICAT$ mild-to-moderate @OBJECT$ , exercise-induced asthma, allergen-induced asthma and aspirin-induced asthma. |
Fact | preserve | 966-977 | 969-977 | T62 | OA patients | PROCESS_OF | 966 | 977 | preserve | 966-968 | 966-968 | T53 | OA | DiseaseOrSyndrome | 966 | 968 | preserve | 969-977 | 969-977 | T54 | patients | PatientOrDisabledGroup | 969 | 977 | A4 | Of the total number of patients studied, 817 (44.7%) were OA patients with a mean (+/- SD) age of 55.8+/-12.9 years, and 1009 (55.3%) were RA patients with a mean age of 53.1+/-13.1 years. | 901-1102 | 901 | 1,102 | Of the total number of patients studied, 817 (44.7%) were @SUBJECT$ @PREDICAT$ @OBJECT$ with a mean (+/- SD) age of 55.8+/-12.9 years, and 1009 (55.3%) were RA patients with a mean age of 53.1+/-13.1 years. |
Fact | preserve | 271-278 | 271-278 | T23 | therapy | TREATS | 271 | 278 | preserve | 241-247 | 241-247 | T12 | NSAIDs | PharmacologicSubstance | 241 | 247 | preserve | 287-291 | 287-291 | T15 | pain | SignOrSymptom | 287 | 291 | A5 | Although NSAIDs are an effective therapy for the pain and inflammation of arthritis, they are associated with serious side effects, particularly ulceration, bleeding, and perforation of the gastrointestinal (GI) tract. | 232-468 | 232 | 468 | Although @SUBJECT$ are an effective @PREDICAT$ for the @OBJECT$ and inflammation of arthritis, they are associated with serious side effects, particularly ulceration, bleeding, and perforation of the gastrointestinal (GI) tract. |
Fact | preserve | 495-506 | 498-506 | T44 | RA patients | PROCESS_OF | 495 | 506 | preserve | 495-497 | 495-497 | T28 | RA | DiseaseOrSyndrome | 495 | 497 | preserve | 498-506 | 498-506 | T29 | patients | PatientOrDisabledGroup | 498 | 506 | A7 | In this study, 1826 OA or RA patients who either had been taking NSAIDS for > or =6 months or had been unable to tolerate continuous NSAID use because of adverse GI symptoms or suspected NSAID-related gastroduodenal lesions were examined endoscopically for gastroduodenal lesions and ulcers. | 469-784 | 469 | 784 | In this study, 1826 OA or @SUBJECT$ @PREDICAT$ @OBJECT$ who either had been taking NSAIDS for > or =6 months or had been unable to tolerate continuous NSAID use because of adverse GI symptoms or suspected NSAID-related gastroduodenal lesions were examined endoscopically for gastroduodenal lesions and ulcers. |
Probable | preserve | 166-173 | 166-173 | T10 | treated | TREATS | 166 | 173 | preserve | 185-221 | 216-221 | T9 | nonsteroidal anti-inflammatory drugs | PharmacologicSubstance | 185 | 221 | preserve | 131-145 | 131-145 | T7 | osteoarthritis | DiseaseOrSyndrome | 131 | 145 | A9 | Rheumatoid arthritis (RA) and osteoarthritis (OA) are frequently treated with nonsteroidal anti-inflammatory drugs (NSAIDs). | 101-231 | 101 | 231 | Rheumatoid arthritis (RA) and @OBJECT$ (OA) are frequently @PREDICAT$ with @SUBJECT$ (NSAIDs). |
Fact | preserve | 46-53 | 46-53 | T5 | induced | CAUSES | 46 | 53 | preserve | 57-99 | 94-99 | T4 | nonsteroidal anti-inflammatory drugs | PharmacologicSubstance | 57 | 99 | preserve | 38-45 | 38-45 | T3 | lesions | Finding | 38 | 45 | A11 | An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. | 0-100 | 0 | 100 | An endoscopic study of gastroduodenal @OBJECT$ @PREDICAT$ by @SUBJECT$ . |
Fact | preserve | 1863-1865 | 1863-1865 | T109 | in | PROCESS_OF | 1,863 | 1,865 | preserve | 1838-1852 | 1846-1852 | T98 | gastric ulcers | AnatomicalAbnormality | 1,838 | 1,852 | preserve | 1866-1874 | 1866-1874 | T99 | patients | PatientOrDisabledGroup | 1,866 | 1,874 | A12 | The prevalence of gastric ulcers was 32.6% in patients with a history of gastric ulcer but only 13.5% in patients with no GI history (previous gastric ulcer, duodenal ulcer, or upper GI hemorrhage). | 1820-2031 | 1,820 | 2,031 | The prevalence of @SUBJECT$ was 32.6% @PREDICAT$ @OBJECT$ with a history of gastric ulcer but only 13.5% in patients with no GI history (previous gastric ulcer, duodenal ulcer, or upper GI hemorrhage). |
Probable | preserve | 166-173 | 166-173 | T10 | treated | TREATS | 166 | 173 | preserve | 185-221 | 216-221 | T9 | nonsteroidal anti-inflammatory drugs | PharmacologicSubstance | 185 | 221 | preserve | 101-121 | 112-121 | T6 | Rheumatoid arthritis | DiseaseOrSyndrome | 101 | 121 | A13 | Rheumatoid arthritis (RA) and osteoarthritis (OA) are frequently treated with nonsteroidal anti-inflammatory drugs (NSAIDs). | 101-231 | 101 | 231 | @OBJECT$ (RA) and osteoarthritis (OA) are frequently @PREDICAT$ with @SUBJECT$ (NSAIDs). |
Fact | preserve | 1053-1064 | 1056-1064 | T63 | RA patients | PROCESS_OF | 1,053 | 1,064 | preserve | 1053-1055 | 1053-1055 | T58 | RA | DiseaseOrSyndrome | 1,053 | 1,055 | preserve | 1056-1064 | 1056-1064 | T59 | patients | PatientOrDisabledGroup | 1,056 | 1,064 | A14 | Of the total number of patients studied, 817 (44.7%) were OA patients with a mean (+/- SD) age of 55.8+/-12.9 years, and 1009 (55.3%) were RA patients with a mean age of 53.1+/-13.1 years. | 901-1102 | 901 | 1,102 | Of the total number of patients studied, 817 (44.7%) were OA patients with a mean (+/- SD) age of 55.8+/-12.9 years, and 1009 (55.3%) were @SUBJECT$ @PREDICAT$ @OBJECT$ with a mean age of 53.1+/-13.1 years. |
Fact | preserve | 271-278 | 271-278 | T23 | therapy | TREATS | 271 | 278 | preserve | 241-247 | 241-247 | T12 | NSAIDs | PharmacologicSubstance | 241 | 247 | preserve | 296-308 | 296-308 | T16 | inflammation | PathologicFunction | 296 | 308 | A15 | Although NSAIDs are an effective therapy for the pain and inflammation of arthritis, they are associated with serious side effects, particularly ulceration, bleeding, and perforation of the gastrointestinal (GI) tract. | 232-468 | 232 | 468 | Although @SUBJECT$ are an effective @PREDICAT$ for the pain and @OBJECT$ of arthritis, they are associated with serious side effects, particularly ulceration, bleeding, and perforation of the gastrointestinal (GI) tract. |
Fact | preserve | 2214-2225 | 2223-2225 | T120 | disease (RA | ISA | 2,214 | 2,225 | preserve | 2223-2225 | 2223-2225 | T118 | RA | DiseaseOrSyndrome | 2,223 | 2,225 | preserve | 2214-2221 | 2214-2221 | T117 | disease | DiseaseOrSyndrome | 2,214 | 2,221 | A16 | No relationship was found between the prevalence of gastroduodenal ulcers and sex (men, 22.4%; women, 24.9%) or prevalence of gastroduodenal ulcers and type of arthritic disease (RA, 23.6%; OA, 24.5%). | 2032-2252 | 2,032 | 2,252 | No relationship was found between the prevalence of gastroduodenal ulcers and sex (men, 22.4%; women, 24.9%) or prevalence of gastroduodenal ulcers and type of arthritic @OBJECT$ @PREDICAT$ @SUBJECT$ , 23.6%; OA, 24.5%). |
Fact | preserve | 435-453 | 445-453 | T30 | Alzheimer patients | PROCESS_OF | 435 | 453 | preserve | 435-444 | 435-444 | T24 | Alzheimer | DiseaseOrSyndrome | 435 | 444 | preserve | 445-453 | 445-453 | T25 | patients | PatientOrDisabledGroup | 445 | 453 | A1 | The study was performed in 306 subjects; 74 Alzheimer patients diagnosed according to NINCDS-ADRDRA criteria and 232 age and sex-matched controls. | 385-543 | 385 | 543 | The study was performed in 306 subjects; 74 @SUBJECT$ @PREDICAT$ @OBJECT$ diagnosed according to NINCDS-ADRDRA criteria and 232 age and sex-matched controls. |
Fact | preserve | 1532-1537 | 1532-1537 | T97 | using | ADMINISTERED_TO | 1,532 | 1,537 | preserve | 1556-1558 | 1556-1558 | T94 | GC | Hormone | 1,556 | 1,558 | preserve | 1523-1531 | 1523-1531 | T92 | patients | PatientOrDisabledGroup | 1,523 | 1,531 | A1 | MoDC from patients using inhalation GC showed a decreased accessory potency. | 1513-1596 | 1,513 | 1,596 | MoDC from @OBJECT$ @PREDICAT$ inhalation @SUBJECT$ showed a decreased accessory potency. |